logo
Benchmarks extend losses for third session in a row; Sensex down 636.24 pts

Benchmarks extend losses for third session in a row; Sensex down 636.24 pts

Equity benchmark indices Sensex and Nifty tumbled nearly 1 per cent on Tuesday, weighed down by a widespread selloff amid foreign fund outflows and growing geopolitical uncertainties.
Domestic markets fell for the third straight session as investors offloaded energy, finance, and IT stocks, traders said.
In a volatile trading session, the 30-share BSE index dipped 636.24 points or 0.78 per cent to settle at 80,737.51. The NSE Nifty plunged 174.1 points or 0.7 per cent to settle at 24,542.50.
As many as 2,266 stocks declined, while 1,731 advanced and 147 remained unchanged on the BSE.
On Tuesday, Foreign Portfolio Investors (FPIs) were the net sellers to the tune of ₹2,854 crore, while domestic institutional investors (DIIs) bought shares worth ₹5,908 crore. FPIs turned net sellers in June after making their largest net purchase of ₹19,860 crore in May, the highest in eight months.
ICICI Bank and HDFC Bank were the biggest contributors to the Sensex decline, falling 0.9 per cent and 0.4 per cent respectively. Both stocks have significant FPI ownership. The FPI selling came as the OECD slashed its global economic growth forecasts for the second time this year, citing US trade policies. The Paris-based organisation stated that trade barriers are eroding confidence, hindering investments, and exacerbating inflationary pressures.
Adani stocks decline
Shares of Adani group companies declined following a news report alleging that US prosecutors were investigating whether Adani entities had imported Iranian LPG into India via their Mundra port.
The report highlighted that tankers travelling between the Gulf and Mundra port allegedly exhibited traits common to ships evading sanctions. The US Justice Department was reportedly reviewing the activities of several LPG tankers used to ship cargoes to Adani Enterprises. The Adani group dismissed the report as baseless and mischievous, stating they were unaware of any investigation by US authorities. Adani Ports saw the largest decline among Adani stocks, falling 2.4 per cent.
'Optimism over a potential RBI rate cut was offset by global concerns around trade tariffs and rising geopolitical tensions. Attention is likely to shift towards monsoon-linked themes and interest rate-sensitive sectors, such as PSU banks and real estate, amid hopes that monetary easing will support economic momentum. With the Q4 earnings season largely behind us, markets are expected to remain in a consolidation phase as participants shift focus to key macro trends and global cues,' said Siddhartha Khemka, Head of Research, Wealth Management, Motilal Oswal Financial Services.
Twelve of the thirteen major sectors logged losses.
'The domestic market remained in negative territory amid mixed global cues, geopolitical issues, and a volatile currency market led by a weak US dollar. Profit booking was evident across sectors, except for real estate stocks, which were supported by expectations of an interest rate cut by the RBI," said Vinod Nair, head of research, Geojit Financial Services.
"Mid- and small-cap stocks are experiencing relatively less consolidation than large caps due to better earnings growth and moderation in premium valuation. While short-term consolidation is likely to persist, strong domestic-oriented players are estimated to outperform against external volatility,' Nair added.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Realty shares zoom ahead of RBI monetary policy decision
Realty shares zoom ahead of RBI monetary policy decision

New Indian Express

time32 minutes ago

  • New Indian Express

Realty shares zoom ahead of RBI monetary policy decision

Real estate stocks jumped as much as 10% on Thursday in anticipation of the RBI's Monetary Policy Committee (MPC) decision, scheduled for Friday. Market expectations are tilted toward a 25-basis-point repo rate cut, along with a continued accommodative stance—a positive signal for rate-sensitive sectors like real estate. The Nifty Realty index was the top-performing sectoral index on Thursday, climbing up to 2% in intraday trade before settling 1.75% higher. Since May 9, the realty index has surged more than 20%, outpacing the 3% gain made by the benchmark Nifty50 index. Meanwhile, India's equity market extended gains on Thursday as the BSE Sensex surged 443.79 points or 0.55% to close at 81,442.04, and the NSE Nifty50 advanced 130.70 points or 0.53% to settle at 24,750.90. Investors demonstrated robust demand for real estate stocks in anticipation of the RBI's upcoming policy decision on Friday. Market experts widely expect a 25-basis-point reduction in the repo rate -marking the third consecutive cut - as inflationary pressures ease. A small fraction also hopes the RBI goes for a 50 bps rate cut after retail inflation dropped to 3.16% in April, giving the central bank wider flexibility to prioritize economic expansion.

CtrlS Datacenters to power BSE's critical digital infrastructure
CtrlS Datacenters to power BSE's critical digital infrastructure

Time of India

timean hour ago

  • Time of India

CtrlS Datacenters to power BSE's critical digital infrastructure

CtrlS Datacenters to power BSE's critical digital infrastructure HYDERABAD: CtrlS Datacenters Ltd has entered a strategic partnership with the Bombay Stock Exchange (BSE) to power critical data centre infrastructure for the premier financial institution that caters to over 11 crore investors and processes over 700 crore daily transactions. With trading transitioning to electronic platforms, reliable digital infrastructure has become essential for maintaining market integrity, ensuring transaction security, and providing seamless access to financial services. The strategic collaboration underscores the critical role data centres play in modern financial markets, CtrlS said. Stressing on the need for world-class technology that is capable of supporting critical transactions, BSE CEO and managing director Sundararaman Ramamurthy said data centre infrastructure is crucial for stock exchanges. 'The shift to electronic trading has been a significant factor in the stock exchanges' use of data centres.' CtrlS Datacenters founder & CEO Sridhar Pinnapureddy said: 'The scale and criticality of BSE's operations represent not just a technological challenge, but a responsibility to India's economic sovereignty and growth.' 'Every transaction processed through our infrastructure impacts investors, businesses, and ultimately, the nation's financial health. We have engineered our solutions to deliver uncompromising reliability, microsecond-level performance, and ironclad security that BSE's operations demand,' he added. Set up in 1875, BSE is Asia's first and largest stock exchange. It is ranked the sixth largest globally by market capitalisation of around Rs 400 lakh crores (US$4.6 trillion approx) across over 5,500 listed companies. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now

Wockhardt eyes $9 bn market opportunity for novel antibiotic Zaynich
Wockhardt eyes $9 bn market opportunity for novel antibiotic Zaynich

Business Standard

time2 hours ago

  • Business Standard

Wockhardt eyes $9 bn market opportunity for novel antibiotic Zaynich

Mumbai-based pharmaceutical major Wockhardt, which is set to launch a new class of antibiotic, Zaynich, in India this year, estimates a total addressable market opportunity of $9 billion. This includes a $7-billion market in the US and Europe, and a ₹17,000-crore opportunity in India. The company's stock rose 2.4 per cent on the BSE on Thursday following an investor presentation outlining its growth plans for the next three to five years. Zaynich (or WCK 5222) is a key research candidate in Wockhardt's pipeline. It has completed global Phase 3 clinical trials, demonstrating a 20 per cent higher (statistically superior) composite cure rate compared to Meropenem, the current gold standard in antibiotics. Wockhardt claims Zaynich is the first new class of antibiotic in over 30 years to treat gram-negative infections. The drug has already saved 51 lives under compassionate use, including three in the US, where patients had failed all existing therapies. Zaynich is indicated for complicated urinary tract infections (UTIs), hospital-acquired and ventilator-associated bacterial pneumonia, bloodstream infections, and complicated intra-abdominal infections. The company expects approval from the Drugs Controller General of India (DCGI) shortly and plans to launch the drug in the second half of this financial year. Wockhardt has completed a pre-NDA (New Drug Application) meeting with the US Food and Drug Administration (USFDA) in May and plans to file in Q2FY26, targeting a potential launch in FY27. Regulatory filings in the EU and emerging markets are scheduled for the second half of FY26. Wockhardt estimates that around 1.1 million patients in India may benefit from Zaynich, while 371,000 carbapenem-resistant cases in the US and Europe are potential candidates. Overall, there are 4.3 million hospitalised cases involving key gram-negative pathogens in the US and EU. The firm sees a combined addressable patient pool of 2 million across India, the US, Europe, and China. Apart from Zaynich, Wockhardt is also betting on other antibiotics in its portfolio, such as Miqnaf (Nafithromycin), and its biotechnology portfolio, including insulin products. Miqnaf, already launched in India, treats community-acquired bacterial pneumonia (CABP) and upper respiratory tract infections. It has received Qualified Infectious Disease Product (QIDP) status from the USFDA, signifying unmet medical need, and Breakthrough Medicinal Product (BMP) designation in Saudi Arabia. Miqnaf targets a ₹10,800-crore market in India, with over 96 million potential prescriptions. In the biosimilars segment, Wockhardt is focusing on diabetes care and sees significant opportunity arising as Danish major Novo Nordisk phases out human insulin cartridges. This creates a ₹450-crore opportunity in India and a $157-million market across emerging economies. With only three major players in India, including itself, Wockhardt expects to benefit substantially. The company is doubling its diabetes biosimilars capacity over the next three years to meet growing demand, targeting business growth of 20–25 per cent.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store